Morgan Stanley Theravance Biopharma, Inc. Transaction History

Morgan Stanley

$1.36 Trillion
Q1 2025

A detailed history of Morgan Stanley transactions in Theravance Biopharma, Inc. stock. As of the latest transaction made, Morgan Stanley holds 384,987 shares of TBPH stock, worth $4.26 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

384,987

Previous 392,333 1.87%

Holding current value

$4.26 Million

Previous $3.69 Million 6.88%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$8.44 - $10.47 $62,000 - $76,912	-7,346 Reduced 1.87%	384,987 $3.44 Million
Q4 2024 Feb 14, 2025	SELL	$7.93 - $10.08 $820,596 - $1.04 Million	-103,480 Reduced 20.87%	392,333 $3.69 Million
Q3 2024 May 14, 2025	BUY	$7.66 - $10.25 $282,577 - $378,122	36,890 Added 8.04%	495,813 $4 Million
Q3 2024 Nov 14, 2024	BUY	$7.66 - $10.25 $282,577 - $378,122	36,890 Added 8.04%	495,813 $4 Million
Q2 2024 May 14, 2025	BUY	$8.29 - $9.92 $552,031 - $660,572	66,590 Added 16.97%	458,923 $3.89 Million
Q2 2024 Oct 17, 2024	BUY	$8.29 - $9.92 $330,024 - $394,915	39,810 Added 9.5%	458,923 $3.89 Million
Q2 2024 Aug 14, 2024	BUY	$8.29 - $9.92 $330,024 - $394,915	39,810 Added 9.5%	458,923 $3.89 Million
Q1 2024 Oct 17, 2024	SELL	$8.22 - $11.59 $327,238 - $461,397	-39,810 Reduced 8.67%	419,113 $3.76 Million
Q1 2024 Aug 16, 2024	BUY	$8.22 - $11.59 $1.28 Million - $1.8 Million	155,664 Added 59.09%	419,113 $3.76 Million
Q1 2024 May 15, 2024	BUY	$8.22 - $11.59 $1.28 Million - $1.8 Million	155,664 Added 59.09%	419,113 $3.76 Million
Q4 2023 Aug 16, 2024	SELL	$8.58 - $11.4 $1.68 Million - $2.23 Million	-195,474 Reduced 42.59%	263,449 $2.96 Million
Q4 2023 Feb 13, 2024	BUY	$8.58 - $11.4 $92,904 - $123,439	10,828 Added 4.29%	263,449 $2.96 Million
Q3 2023 Nov 15, 2023	BUY	$8.38 - $10.44 $246,321 - $306,873	29,394 Added 13.17%	252,621 $2.18 Million
Q2 2023 Aug 14, 2023	SELL	$10.16 - $11.92 $1.32 Million - $1.55 Million	-129,676 Reduced 36.75%	223,227 $2.31 Million
Q1 2023 May 15, 2023	SELL	$9.87 - $11.44 $1.33 Million - $1.54 Million	-134,920 Reduced 27.66%	352,903 $3.83 Million
Q4 2022 Feb 14, 2023	SELL	$9.65 - $11.34 $1.07 Million - $1.26 Million	-110,842 Reduced 18.51%	487,823 $5.47 Million
Q3 2022 Nov 14, 2022	BUY	$8.39 - $10.22 $1.72 Million - $2.1 Million	205,080 Added 52.11%	598,665 $6.07 Million
Q2 2022 Oct 27, 2022	SELL	$8.41 - $10.34 $2.32 Million - $2.86 Million	-276,419 Reduced 41.26%	393,585 $3.57 Million
Q2 2022 Aug 15, 2022	SELL	$8.41 - $10.34 $2.32 Million - $2.86 Million	-276,419 Reduced 41.26%	393,585 $3.57 Million
Q1 2022 Oct 27, 2022	BUY	$8.33 - $12.96 $2.3 Million - $3.58 Million	276,419 Added 70.23%	670,004 $6.41 Million
Q1 2022 May 13, 2022	SELL	$8.33 - $12.96 $6.74 Million - $10.5 Million	-809,025 Reduced 54.7%	670,004 $6.41 Million
Q4 2021 Feb 14, 2022	BUY	$7.42 - $11.05 $7.05 Million - $10.5 Million	950,477 Added 179.83%	1,479,029 $16.3 Million
Q3 2021 Nov 15, 2021	BUY	$6.77 - $14.41 $3.58 Million - $7.62 Million	528,552 New	528,552 $3.91 Million

Others Institutions Holding TBPH

# of Institutions

137

Shares Held

47.2M

Call Options Held

700

Put Options Held

1.4K

View Full List

About Theravance Biopharma, Inc.

Ticker TBPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 66,782,400
Market Cap $739M
Description
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also inc...

More about TBPH

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account